This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

John Mei
John Mei
Associate
New York +1 212 841 1192 jmei@cov.com Download V-card

John Mei is a member of the firm’s Corporate Practice Group and focuses on securities and capital markets, mergers and acquisitions, and finance transactions. His experience includes representing U.S. and international clients in a range of equity and debt offerings; public and private mergers, acquisitions and joint ventures; and secured and unsecured loan transactions. He also advises clients in connection with corporate governance and general corporate matters.

Securities and Capital Markets

  • Represented the underwriters in the $138 million follow-on offering of common stock by Repligen Corporation, a bioprocessing company focused on products used to manufacture and purify biologic drugs.
  • Represented the underwriters in the $67 million initial public offering of ordinary shares of UroGen Pharma Ltd., an Israeli biopharmaceutical company focused on uro-oncology.
  • Represented a diagnostics company focused on immune-regulated conditions in a $40 million follow-on offering.
  • Represented a global animal health company in multiple investment-grade notes offerings totaling $2.5 billion.
  • Represented the underwriters in multiple follow-on and at-the-market offerings of Affimed N.V., a Dutch biotechnology company focused on immuno-oncology.

Finance

  • Represented a private investment fund focused on debt and royalty financings for pharmaceutical, biotechnology, medical device and healthcare companies in multiple secured debt, royalty and equity financings.
  • Represented a diagnostics company in a $40 million secured term and revolving credit facility.
  • Represented The Goodyear Tire & Rubber Company in the refinancing of the €550 million revolving credit facility for its European businesses.

Mergers and Acquisitions

  • Represented a leading global pharmaceutical company in multiple acquisitions of clinical-stage biotechnology companies.
  • Represented healthcare network in spin-off and joint venture of healthcare technology management services division.